Skip to main content
ASPHO Logo
Menu Journal My Account Contact Join/Renew
Login
  • Meetings & Events
    • Conference
      • 2025 Conference
      • Continuing Education
      • Press | 2018 Conference
      • 2018 Call for Papers and Posters
        • Back to Meetings
        • 2019 Conference
        • Schedule of Events
        • Registration Rates
        • Conference Planning Committee
        • Conference Hotel and Travel
        • Faculty
        • 2019 Call for Papers and Posters
        • Continuing Education
        • PBMTC
        • Accepted Papers and Posters
        • MOC Opportunities
        • App - Thank you for Attending
        • 2019 Attendee List
      • 2018 Conference
        • Schedule of Events
        • Accepted Papers and Posters
      • 2016 Annual Meeting
        • Overview
        • Attendee List
        • ASPHO Virtual Bag
        • Corporate Forum Symposia/Education Theaters
        • Accepted Papers and Posters
          • Accepted A-G
          • Accepted H-M
          • Accepted N-Z
          • 2016 Searchable Abstract Database
        • Exhibit Hall
        • Sponsors
        • Annual Meeting Brochure
        • Virtual Bag
        • Schedule of Events
        • Continuing Education
        • Attendee List
        • 2017 Searchable Abstract Database
        • Accepted Papers and Posters
        • Corporate Forum Symposia/Education Theater
        • Travel
        • Program Committee
        • Commercial Support
        • Exhibit with ASPHO
      • Registration
      • Commercial Support
      • Meetings Archive
      • Registration Information
      • 2026 Conference
      • 2026 Call for Workshops
    • Review Course
      • Anderson 2019
      • McClain 2019
      • Adams 2019
      • Moran 2019
      • Effinger 2019
      • Fangusaro 2021
      • Brown 2021
      • Young 2021
      • Harker-Murray 2021
      • Effinger 2021
      • Pai 2021
      • Grace 2021
      • Rogers 2021
      • Anderson 2021
      • Powers 2021
      • McClain 2021
      • Neunert 2021
      • Fleming 2021
      • Mullen 2021
      • Pommert 2021
      • Meade 2021
      • Greengard 2021
      • Fox 2021
      • Bercovitz 2021
      • Brock 2021
      • Adams 2021
      • Loh 2021
      • O'Brien 2021
      • Walterhouse 2021
      • Pulsipher 2021
      • Oberley 2021
      • Rodriguez-Galindo 2021
      • Kesselheim 2021
      • Frei-Jones 2021
      • Allen 2021
      • 2015 Online Review Course CME Certificates
      • 2019 Planning Committee
      • 2019 Schedule
      • 2019 Travel
      • 2019 Review Course Early Career
      • 2019 Review Course Directors
        • 2019 Review Course Faculty
      • Oberley 2019
      • O'Brien 2019
      • Pai 2019
      • Pulsipher 2019
      • Rodriguez-Galindo 2019
      • Rogers 2019
      • Walterhouse 2019
      • Young 2019
      • Park 2019
      • Malec 2019
      • Evaluations
      • Brown 2019
      • Allen 2019
      • Fangusaro 2019
      • Fleming 2019
      • Frei-Jones 2019
      • Grace 2019
      • Harker-Murray 2019
      • Heeney 2019
      • Kesselheim 2019
      • Loh 2019
      • Mascarenhas 2019
      • Neunert 2019
      • Fangusaro 2023
      • Adams 2023
      • Neunert 2023
      • Oberley 2023
      • Grace 2023
      • Effinger 2023
      • Nakano 2023
      • Brock 2023
      • Harker-Murray 2023
      • Meade 2023
      • Fleming 2023
      • Kesselheim
      • Kumar 2023
      • Anderson 2023
      • Malogolowkin 2023
      • Pommert 2023
      • Bercovitz 2023
      • Frei-Jones 2023
      • O'Brien 2023
      • Pai 2023
      • Young 2023
      • Fox 2023
      • Powers 2023
      • Pulsipher 2023
      • McClain 2023
      • Loh 2023
      • Greengard 2023
      • Frazier 2023
      • Brennan 2023
      • Walkovich 2023
      • Browning 2023
      • Mullen 2023
      • 2025 Review Course
        • 2025 Faculty
        • 2025 Learning Objectives and CME
        • 2025 Schedule
        • 2025 Cancellation Policies and Disclosures
        • 2025 Planning Committee
        • Young 2025
        • Bercovitz 2025
        • Brennan 2025
        • Fangusaro 2025
        • Fox 2025
        • Frazier 2025
        • Greengard 2025
        • O'Brien 2025
        • Pommert 2025
        • Powers 2025
        • Pulsipher 2025
        • Walkovich 2025
        • Neunert 2025
        • Adams 2025
        • Oberley 2025
        • Grace 2025
        • Effinger 2025
        • Nakano 2025
        • Brock 2025
        • Harker-Murray 2025
        • Meade 2025
        • Fleming 2025
        • Kesselheim 2025
        • Kumar 2025
        • Creary 2025
        • DeNardo 2025
        • Dome 2025
        • Jordan 2025
        • McCavit 2025
        • Pai 2025
        • Raetz 2025
        • Malogolowkin 2025
        • Terrell 2025
        • Kucine 2025
      • Learning Objectives and CME
      • Faculty
      • Schedule
      • Policies
    • Events Calendar
  • Knowledge Center
    • Products
      • KARE Toolkit: Knowledge and Assessment Resources
        • CME for KARE
        • CME for RC On-Demand
        • CME for PHO Review Course On Demand
        • CME for KARE Plus
        • CME for KARE Plus Hematology
        • CME for KARE Plus Oncology
        • The KARE Toolkit - Index of Topics
      • Webinars
      • ASPHOcast
      • Alexion Recording
      • 2024 Compensation Survey
      • Webinar Toolkit
      • Compensation and Benefits Report
      • View the Compensation and Benefits Survey Report
      • Compensation Tool
    • Online Review Course
    • Pediatric Blood & Cancer
      • Access Journal
      • Online Access Instructions
    • ASPHO eNews
      • August 2015 Enews
      • June 2015 Enews
      • April 2015 Enews
      • February 2015 Enews
      • December 2014 Enews
      • October 2014 Enews
      • August 2014 Enews
      • June 2014 Enews
      • April 2014 Enews
      • February 2014 Enews
      • December 2013 Enews
      • October 2013 Enews
      • August 2013 Enews
      • June 2013 Enews
      • April 2013 Enews
      • February 2013 Enews
      • October 2014 Enews
      • October 2015 Enews
      • December 2015 Enews
      • February 2016 Enews
      • April 2016 Enews
      • June 2016 Enews
        • DSIG Student Registration
      • August 2016 Enews
      • October 2016 Enews
      • December 2016 Enews
      • February 2017 Enews
      • April 2017 Enews
      • June 2017 Enews
      • August 2017 Enews
      • October 2017 Enews
      • December 2017 Enews
      • February 2018 Enews
      • April 2018 Enews
      • June 2018 Enews
      • August 2018 eNews
      • October 2018 eNews
      • February 2019 eNews
      • Member Insights: eNews 2018 Highlights
      • April 2019 eNews
      • June 2019 eNews
      • August 2019 eNews
      • October 2019 eNews
      • December 2019 eNews
      • February 2020 eNews
      • April 2020 eNews
      • June 2020 eNews
      • August 2020 eNews
      • October 2020 eNews
      • December 2020 eNews
      • April 2021 eNews
      • June 2021 eNews
      • August 2021 eNews
        • August 2021 President's Message
      • December 2021 eNews
      • February 2022 eNews
      • April 2022 eNews
      • June 2022 eNews
      • August 2022 eNews
      • October 2022 eNews
      • December 2022 eNews
      • February 2023 eNews
      • April 2023 eNews
      • June 2023 eNews
      • October 2023 eNews
      • December 2023 eNews
      • February 2024 eNews
      • March 2024 eNews
      • April 2024 eNews
      • June 2024 eNews
      • August 2024 eNews
      • October 2024 eNews
      • December 2024 eNews
      • February 2025 eNews
      • April 2025 eNews
      • June 2025 eNews
    • Pediatric Blood & Cancer - Call for Applications for Deputy Editor
    • October 2015 Enews
    • Advocacy Sample
    • News Briefs
    • Health Policy & Advocacy
      • 2016 August Advocacy Brief
      • 2016 December Advocacy Brief
      • 2017 February Advocacy Brief
      • 2017 May Advocacy Brief
      • 2017 September Advocacy Brief
      • 2017 November Advocacy Brief
      • 2018 Advocacy Brief - March
      • Contact Your Members of Congress
      • 2018-Advocacy-Brief-June
      • 2018-Advocacy-Brief-September
      • Advocacy Brief December 2018
      • 2019 Advocacy Brief - March
      • March 2019 Advocacy Brief
      • June 2019 Advocacy Brief
      • September 2019 Advocacy Brief
      • March 2020 Advocacy Brief
      • June 2020 Advocacy Brief
      • September 2020 Advocacy Brief
      • December 2020 Advocacy Brief
      • June 2021 Advocacy Brief
      • September 2021 Advocacy Brief
      • March 2022 Advocacy Brief
      • June 2022 Advocacy Brief
      • September 2022 Advocacy Brief
      • March 2024 Advocacy Brief
      • September 2024 Advocacy Brief
      • December 2024 Advocacy Brief
      • March 2025 Advocacy Brief
    • 2017 Workforce Survey Report
    • Help Fund the STAT Act
    • Practice and Quality
      • Choosing Wisely®
      • Position Paper
      • Endorsements
      • ASPHO Endorsements member only
  • Career Development
    • Mentoring
      • Early Career Mentoring
    • Awards
      • Distinguished Career Award
      • Oski Memorial Lectureship
      • International Travel Awards
      • Buchanan Lectureship
      • Young Investigator Award
      • Young Investigator Form
      • EC Travel Stipend Form
      • Early Career Travel Stipend
      • Advanced Practice Provider Award
      • Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
    • Career Center
    • Fellowship Resources
      • Post-PHO Fellowship Program Directory
      • Fellowship Program Directors' Resources
    • Certification
      • Continuing Medical Education
      • advocating for moc
      • ABP MOC Letter Nov 2015
      • ABP Hematology/Oncology Content Outline
    • 2019 ASPHO Award Recipients
    • Workforce
  • Membership
    • Who Belongs
    • Benefits
    • Join Us
    • Renew
    • Membership Application
    • Fellows Group Application
    • Member Community
    • Find a Member
    • Special Interest Groups
      • Adolescent and Young Adult SIG
      • Advanced Practice Provider SIG
      • Cancer Predisposition SIG
      • Clinical Immunology SIG
      • Diversity SIG
        • 2017 DSIG Travel Award
      • Global Hem Onc SIG
      • Hemoglobinopathy SIG
      • Hospitalist Medicine SIG
      • Informatics, Innovation and Entrepreneurship SIG
      • Integrative Pediatric Hematology/Oncology SIG
      • Palliative Care SIG
      • Physician Scientist SIG
      • Quality Improvement and Patient Safety SIG
      • Small Program SIG
      • Vascular Anomalies SIG
      • Clinical Immunology SIG Webinar
      • Well-Being SIG
    • Enriching the Future
      • ETF Donors
      • ETF FAQ
      • ETF Programs
      • ETF Award Recipients
      • Donate
    • Stay Connected with ASPHO
    • New Member
    • Trainee Membership Level
    • Strengthen Your Everyday Practice
  • About
    • Governance
      • 2017 Election Nominations
      • 2019 Board and Nominating Committee members
      • Board of Trustees
      • Leadership Development & Election Process
      • Nominating FAQs
      • Strategic Plan
        • Leadership Domain
        • Education Domain
        • Career Domain
        • Administration Domain
      • Volunteer Opportunities
        • Early Career Council
    • Policies
      • Advertising Sponsorship
      • Support of CME
      • Committee Policies, Responsibilities, and Resources
      • Conflict of Interest and Disclosure for Volunteers
      • Distinguished Career Award Eligibility Criteria
      • Diversity Statement
      • Investment
      • Member Mailing List
      • Oski Eligibility Criteria
      • Presidential Stipend
      • Records Retention
      • Reserve Fund
      • Reviews and Endorsements
      • Speaker Reimbursement
      • Surveying Members
      • Whistleblower
      • Workshop Session
      • Young Investigator Award
      • Early Career Travel Stipend
      • Buchanan Lectureship Eligibility
      • ASPHO Statements
    • Terms of Use
    • Contact Us
    • 2016 Election Nominations
    • 2015 Election Candidates
    • FDA Approves Dinutuximab
    • Q&A Amy Billett
    • Fund Raising Policy
    • Support and Advertising
      • Exhibit
      • Advertising
      • Industry Relations Council
      • Grants
    • Diversity & Inclusion
    • Donate
    • DEI Member Perspectives
    • Account Access
  • 2017 Annual Meeting Session Recordings
  • 2018 Annual Meeting Session Recordings
  • George R. Buchanan Lectureship Award Presentation
  • Cancer Predispositions in Clinical Practice
  • Evidence and Equipoise in Pediatric Thrombosis - Updates from Randomized Controlled Trials
  • Playing on Our Strengths - Developing Interprofessional Teams in Pediatric Hematology-Oncology
  • Providing Optimal Pediatric Palliative Care: Overcoming the Barriers
  • When in Quebec, Do What the Quebecers Do (Part Deux) - It's All About Platelets!
  • Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Pediatric Patients with ALL in the era of Tyrosine Kinase Inhibitors, Novel Immunotherapies and 'MRD Status'
  • Award Presentations
  • Hemophilic Arthropathy, More Than Meets the Eye: Advances in Early Disease Detection from Clinical Tools to Musculoskeletal Imaging
  • ZFNs, CrispR/Cas9 and TALENS- Oh My!
  • Collaboration in the Treatment of Liver Tumors
  • Leukemia
  • Solid Tumors/Lymphoma
  • Hematology I
  • Beyond Antibodies and CAR T Cells: Challenges and Opportunities in Manipulating the Pediatric Cancer Immunome
  • Blood Clots in Sick Kids: A critical mini-review of venous thrombo-embolism in selected high-risk pediatric populations
  • It's not just about Diversity: Improving the Outcomes for All by Moving toward Equity
  • Children's Oncology Group (COG)
  • Outcomes Research
  • Social Media: The Good, The Bad, and Beyond
  • Sickle Cell Disease in the AYA population: Management Challenges for the Pediatric Hematologist
  • Molecularly Defined Rare Pediatric Sarcomas: An Update for the General Oncologist
  • Mechanisms of Tumor Microenvironment Immune Mediated Resistance and Methods of Therapeutic Circumvention
  • Behind the Scenes at Pediatric Blood & Cancer: Everything You Always Wanted to Know About Getting Published
  • New Insights in Inherited Hematologic Diseases
  • Changing Workforce of Pediatric Hematology/Oncology
  • New Diagnostic and Therapeutic Approaches of Opportunistic (Viral/Fungal) Infections in the Pediatric Cancer Patient
  • New Mutations and Targeted Therapies in Langerhans Cell Histiocytosis
  • Physician, Sustain Thyself: Building Resilience to Prevent Burnout
  • Practicing Precision in Pediatric Oncology: Three Perspectives
  • What's Happening in DC? A Look at ASPHO Advocacy Efforts
  • Critical Care of the Immunocompromised Pediatric Hematology/Oncology Patient
  • Brain Tumors
  • Hematology II
  • Sponsor, Exhibit, and Advertise
    • Exhibits
    • Advertising
    • Industry Relations Council
    • Exhibits Adveritising
  • Ward Testing OSE
  • 2018 Session | George R. Buchanan Lectureship Award Presentation
  • 2018 Session | Plenary Paper Session 2001-2002
  • 2018 Session | St. Baldrick's Foundation Robert J. Arceci Innovation Award Announcement
  • 2018 Session | Plenary Session—Health Care in the Current Political Climate: Stormy Days Ahead?
  • 2018 Session | Pediatric Ependymoma: The Science Driving Patient Care
  • 2018 Session | Iron: Let's Get Pumped
  • 2018 Session | Extracellular Vesicle Trafficking—Biology and Translational Impact in Hematology and Cancer
  • 2018 Session | Relapsed, Refractory, Metastatic Bone Sarcomas: New Insights on Pathogenesis, Prognosis and Treatment
  • 2018 Session | Alpha Thalassemia—A Growing Public Health Disease with Changing Landscape of In-Utero and Post-Natal Therapy
  • 2018 Session | Decision Making in Benign Hematology: Living in a World Without Randomized Trials
  • 2018 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
  • 2018 Session | Early Career Travel Stipend Awards
  • 2018 Session | Young Investigator Award Presentations
  • 2018 Session | Management of Extracranial Germ Cell Tumors in Adolescent and Young Adult Population
  • 2018 Session | Challenging Hematologic Complications Post–Stem Cell Transplantation and Beyond
  • 2018 Session | Advanced Symptom Management and End-of-Life Care: Multidisciplinary Primary Palliative Care for Pediatric Hematologists/Oncologists
  • 2018 Session | Paper Session - Solid Tumor
  • 2018 Session | Paper Session - Hematology
  • 2018 Session | Vascular Anomalies: The Great Mimickers
  • 2018 Session | Addressing Sexual Health in Adolescent and Young Adult Patients: What You Should Know as a Pediatric Hematology/Oncology Care Provider
  • 2018 Session | Navigating Intravascular Bottlenecks: A Critical Mini-Review of Pediatric Venous Thromboembolism in the Setting of an Anatomical Thrombophilia
  • 2018 Session | Paper Session - Children's Oncology Group (COG)
  • 2018 Session | Paper Session - Hematology Science
  • 2018 Session | Can Late Effects be Prevented in Pediatric Oncology?
  • 2018 Session | Clash of the Titans: Debates on Best Management of Patients with Bleeding Disorders
  • 2018 Session | Providing Effective Feedback: The Currency of Conflict Resolution
  • 2018 Session | Recent Advances and New Approaches to Rare Hematological Malignancies
  • 2018 Session | Primary and Secondary Stroke Prevention in Sickle Cell Disease: The Debate
  • 2018 Session | Combating an Unmet Need: Psychosocial Health
  • 2018 Session | Renal Tumors Beyond Wilms
  • 2018 Session | Pediatric and Neonatal Transfusion Medicine
  • 2018 Session | Mobile Applications in Clinical Practice
  • 2018 Session | Presidential Symposium—Partnering with Patients and Families to Improve Research and Clinical Decision-making
  • 2018 Session | Review of Rare Pediatric Head and Neck Tumors for the General Oncologist
  • 2018 Session | Emerging Therapies in Hemophilia
  • 2018 Session | How Should You Treat That Bug? A Debate About Antimicrobial Management in Fever and Neutropenia
  • 2018 Session | Paper Session with Luminary Investigator - Leukemia
  • 2018 Session | Paper Session with Luminary Investigator - Hematology
  • 2018 Session | Frank A. Oski Memorial Lectureship Award Presentation
  • December 2018 eNews
  • 2019 Session | Splenectomy - The Great Debate
  • 2019 Session | DICER1: Updates on Biology and Clinical Management
  • 2019 Session | Burnout in Pediatric Hematology/Oncology: Moving from Discussion to Action
  • 2019 Session | Diagnostic and Management Conundrums Surrounding Women with Heavy Menstrual Bleeding and Underlying Bleeding Disorders
  • 2019 Session | All That Glitters is Not Gold – How We Differentiate Primary HLH from Fake News
  • Models for International Pediatric Oncology Outreach
  • 2019 Session | Navigating Genetic Testing in the Pediatric Hematology Setting
  • 2019 Session | Radiation Therapy for Pediatric Cancer Patients: Updates and New Modalities
  • 2019 Session | The Microbiome: What Is It and Why Do We Care?
  • 2019 Session | Brain Attack: Therapeutic Advances in Neonatal and Childhood Stroke
  • 2019 Session | Advances in Pediatric AML
  • 2019 Session | Improving Medication Adherence for Adolescents and Young Adults: Is Technology the Answer?
  • 2019 Session | Metabolism in Pediatric Hematology/Oncology - Presidential Symposium
  • 2019 Session | Too Much of a Good Thing – Myeloproliferation in Children
  • 2019 Session | Multiple Bony Lytic Lesions, but Not Langerhans Cell Histiocytosis (LCH) – Now What?
  • 2019 Session | Savior Siblings: Medical, Ethical, and Psychosocial Considerations in using Preimplantation Genetic Diagnosis (PGD) to Ensure a Matched Sibling Donor for Hematopoietic Stem Cell Transplantation (HSCT)
  • 2019 Session | George R. Buchanan Lectureship Award Presentation
  • 2019 Session | 2019 St. Baldrick’s Foundation Robert J. Arceci Innovation Award Announcement and Past Recipient Presentation
  • 2019 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship Announcement and Frank A. Oski Memorial Lectureship Award Presentation
  • 2019 Session | New Paradigms for Severe Aplastic Anemia: Genetic Screening, Eltrombopag, and Up Front Unrelated Donor BMT
  • 2019 Session | Not Too Young for That Cancer: Adolescent and Young Adult Carcinomas
  • 2019 Session | Transforming the Treatment of Chronic Pain
  • 2019 Session | Putting an End to End Organ Damage in Sickle Cell Disease
  • 2019 Session | Defining Pediatric MDS: A Morphologic or Molecular Diagnosis?
  • 2019 Session | The Power of One: Present Challenges in Treating Rare Diseases
  • 2019 Session | Hematological Manifestations of Immune Deficiencies and Dysregulatory Disorders: When should you look harder for underlying causes of Autoimmune Cytopenias?
  • 2019 Session | Oncofertility Programs: More Than Just Sperm Banking
  • 2019 Session | The (Financial) Cost of a "Cure"
  • 2019 Session | (2001) Potential Utility of MRD to Identify Relapse in pALL Patients Treated with Tisagenlecleucel
  • 2019 Session | (2002) Lentiglobin Gene Therapy in Transfusion-Dependent Β-Thalassemia Patients with Non-β0/β0 Genotypes
  • 2019 Session | (2003) Mechanisms of Resistance to the Type II JAK2 Inhibitor CHZ868 in B-Cell Acute Lymphoblastic Leukemia
  • 2019 Session | (2004) Discovering Noncoding Genetic Elements that Regulate Globin Synthesis
  • 2019 Session | (2005) Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Safety & Efficacy
  • 2019 Session | (2006) Modeling IKZF1 Lesions in B-cell Acute Lymphoblastic Leukemia Reveals Potential Therapeutic Targets
  • 2019 Session | (2007) Prognostic Determinants in Childhood T-cell Acute Lymphoblastic leukemia: Results of DFCI 05001
  • 2019 Session | (2008) Gap Junction Interference increases Apoptosis in ALL cells and augments effects of Antimetabolites
  • 2019 Session | (2009) Hydroxyurea Lowers Tricuspid Regurgitant Jet Velocity in Children with Sickle Cell Anemia
  • 2019 Session | (2010) Novel Next-Generation Sequence based Assay for Non-Invasive Prenatal Testing of Sickle Cell Disease
  • 2019 Session | (2011) Gabapentin for Pain in Sickle Cell Disease: Results of a Randomized Phase II Clinical Trial
  • 2019 Session | (2012) Quality of Life is the most important Indication for Second-Line ITP Treatment in Children
  • 2019 Session | (2013) BCL2-Inhibitor Response in Neuroblastoma: Biomarkers and Therapy Resistance
  • 2019 Session | (2014) The Clinical Application of Molecular Testing in Pediatric Solid Tumors: An Institutional Experience
  • 2019 Session | (2015) Enhancing Tumor Directed T Cells with an Interleukin-7 Signal Modulator
  • 2019 Session | (2016) Epigenome Screening Identifies Transcriptional Elongation as Therapeutic Vulnerability in DIPG
  • 2019 Session | (2017) Levofloxacin Prophylaxis
  • 2019 Session | (2018) Renal Tumors: Future Roadmap
  • 2019 Session | (2019) Soft Tissue Sarcoma
  • 2019 Session | (2020) Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa
  • 2019 Session | (2021) Leucine for the Treatment of Transfusion Dependence in Patients with Diamond Blackfan Anemia
  • 2019 Session | (2022) A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
  • 2019 Session | (2023) Peripherally Inserted Central Catheters (PICCs), the Leading Cause of Central Venous Catheter Associated Thrombosis in Children
  • 2019 Session | The Role of Survivorship Research in Advancing Childhood Cancer Care and Quality of Survival
  • 2019 Session | (2024) Septic Shock (SS) Incidence in National ALL & AML Cohorts using Administrative & Clinical Trial Data
  • 2019 Session | (2025) Nelarabine Abrogates Relapse Rates in CNS-3 T-ALL: A Report from Children’s Oncology Group AALL0434
  • 2019 Session | (2026) Current Cancer Survivorship Practices: A Report from the Children’s Oncology Group (COG)
  • 2019 Session | (2027) Intra-Arterial Chemotherapy for Retinoblastoma: A 7-year Single Institution Experience
  • 2019 Session | Advancing Discovery in Hematology: Bench to Bedside? No. Bedside to Bench to Bedside...
  • 2019 Session | (2028) The Shwachman Diamond Syndrome Registry: Hematologic Complications
  • 2019 Session | (2029) Characteristics and Outcomes of Unprovoked Venous Thromboembolism in the Pediatric Population
  • 2019 Session | (2030) Third Party VST are an effective Therapy for the Treatment of BK-Virus Reactivation after Transplant
  • 2019 Session | (2031) Inhibition of Nemo-Like Kinase improves Erythropoiesis in Models of Diamond Blackfan Anemia
  • CI SIG Webinar
  • October 2021 eNews
  • 2025 Conference App Download Instructions

eNews

Member Insights: eNews 2020 Highlights

This special eNews issue showcases member-authored Diversity Corner and Special Feature articles that appeared in 2020. Take a look back to appreciate the informative articles and personal reflections written by your colleagues.

Diversity Corner

June 2020

Diversity SIG — ASPHO 2020 and Future Endeavors
Pinki Prasad, MD MPH, Daniel Ortiz, MD, and Kerice Pinkney, MD

Diversity SIG Mission

The Diversity SIG (DSIG) of ASPHO aims to support the advancement of all ASPHO members and the field of pediatric hematology/oncology through increasing diversity and inclusiveness in a broad sense in the membership and leadership of ASPHO, as well as the home institutions of members. ASPHO’s DSIG has made it a top priority for our group’s activity to begin with early outreach and engage medical students before the annual meeting. Our goal is to connect medical students with faculty in the field of pediatric hematology/oncology at the ASPHO Conference.

The physician workforce continues to struggle with adequate representation of racial and ethnic minorities, with hematology and oncology lagging behind medicine in general. According to the most recent census, 13% of the US population is black or African American and 18% is Hispanic.1 In contrast, only 2.3% of practicing oncologists self-identified as black or African American and 5.8% of practicing oncologists self-identified as Hispanic.2,3,4

Individuals from populations underrepresented in medicine are even more underrepresented in oncology than in fellowship or residency programs in general. Thus, early outreach is essential for mentoring medical students and residents who are interested in pediatric hematology/oncology as a career choice.

Medical School Partnership

To further our commitment to mentoring in 2020, the DSIG collaborated with University of North Texas Health Sciences Center (UN THSC) in Fort Worth, TX. Our SIG started planning a meet and greet with the UN THSC medical students and faculty in late 2019 and had over 30 students signed up for the meet and greet. Twenty-three students were interested in being paired with an ASPHO mentor during the 2020 conference. UN THSC showed tremendous generosity to the DSIG, and we are disappointed that this year’s meeting was cancelled. We are hopeful that we can continue to work with the students and have some of them attend the 2021 ASPHO Conference.

Collaboration with other SIGs

Other themes of the DSIG include identifying and overcoming barriers to academic success for women and historically underrepresented minorities. The DSIG was able to partner with the Hemoglobinopathy SIG to develop an ASPHO Webinar Series webinar hosted on October 30, 2019, Harnessing Diversity to Improve Outcomes for Children with Blood Disorders and Cancer. The webinar was moderated by Dr. Monica Hulbert, and speakers included Dr. Kira Bona and Dr. Emily Meier.

In the United States, children of minority racial/ethnic backgrounds with acute lymphoblastic leukemia have worse outcomes than nonminority children. Children and adults with sickle cell disease face barriers to medication adherence and difficulty obtaining acute and chronic care. Individuals with sickle trait may not be provided appropriate genetic counseling information. The webinar discussed how increasing understanding of diversity in the medical setting can help identify and mitigate barriers to care, in turn improving outcomes for children of minority backgrounds with hemoglobinopathies and cancer. Cultural/racial barriers to optimal clinical care, genetic counseling, and medication adherence for children with blood disorders and cancer were discussed. Other topics included identifying the impact of increasing diversity of local care teams on patient outcomes and discussing strategies for increasing diversity within the care team.

This year we were excited to plan to jointly host a speaker with the Hemoglobinopathy SIG and the Physician Scientist SIG, Dr. Lydia Pecker, to discuss her academic career path in sickle cell disease and research. In addition, the DSIG was invited to join a grant writing and research session with the Physician Scientist SIG as a second part to Dr. Pecker’s presentation.

Although the DSIG is disappointed that the ASPHO Conference was cancelled in 2020, we are looking forward to a safe and successful meeting in 2021. We welcome new members to join our Diversity Special Interest Group. We communicate throughout the year using ASPHO’s Member Community.

References:

  1. US Census. QuickFacts. United States. https://www.census.gov/quickfacts/table/PST045215/00. Accessed June 1, 2020.
  2. Kirkwood MK, Hanley A, Bruinooge SS, et al. The state of oncology practice in America, 2018: results of the ASCO Practice Census Survey. J Oncol Pract. 2018 Jul;14(7):e412-e420. doi: 10.1200/JOP.18.00149.
  3. American Academy of Pediatrics. Demographics of women physicians and pediatricians. https://www.aap.org/en-us/about-the-aap/departments-and-divisions/department-of-education/Documents/women_med_demographics.pdf. Accessed June 24, 2016.
  4. Association of American Medical Colleges. Table 3. Distribution of U.S. medical school faculty by rank and race/ethnicity. https://www.aamc.org/download/453416/data/15table3.pdf. Accessed June 24, 2016.

October 2020

Being Informed and Taking Action: ASPHO's Member Experience and Diversity Needs Assessment
Eleny Romanos-Sirakis, MD, Nidhi Shah, DO, and Betty Pace, MD

In these times of uncertainty and change, it is important to know ASPHO's principles of inclusion and diversity.

Our medical profession and the nation are being tested in the face of racial tension and the COVID-19 pandemic, which has sharply drawn attention to inequities impacting patient care as well as diversity issues within the profession. Coinciding with these societal upheavals, the Board of Trustees recently reviewed the Member Experience and Diversity Needs Assessment results about member engagement; benefits; and, importantly, perceptions of diversity at ASPHO. Key takeaways from the survey conducted last fall by the Membership Committee and Diversity Advisory Group follow. Of special note are recommendations by the Diversity Advisory Group, fulfilling its charge "to advise the Board of Trustees on the needs and opportunities for promoting diversity, inclusion, and cultural competency within the Society as guided by ASPHO's Diversity Statement."

We are pleased to relay highlights from the survey. We also encourage you to read ASPHO's Anti-Racism and Healthcare Equity Statement and Dr. Jorge Di Paola's June President's Message to gain a better sense of the Society's values regarding representing and supporting members. In addition, ASPHO is proud to have both a Board-appointed Diversity Advisory Group and a Diversity Special Interest Group that is open to all members.

The majority of respondents were either "satisfied" or "very satisfied" with their membership. Key responses regarding the member experience follow.

  • The majority of "very satisfied" members were mid-late career specialists who had volunteered in the past 5 years and have a primary interest in expanding their professional network. Twenty percent of respondents felt "very engaged," with close to 40% responding with "slightly engaged." Mid-late career specialists felt more engaged and satisfied than early career specialists.
  • Reasons for joining vary by race/ethnicity. The top three reasons for non-white respondents were educational programs and resources, to be part of a community of peers, and to advance their careers. White respondents also noted education for the first reason, with staying current on developments and treatments as the second draw, and the third reason was a tie between expanding professional network and being part of a community of peers.
  • Non-white members volunteered and attended the ASPHO Conference at slightly higher rates than white members.

Highlights of diversity-related responses follow.

  • Approximately one-half of ASPHO survey respondents (44%–47%) did not know demographic data about ASPHO's leadership, committees, or programming participants like mentors, speakers, and presenters and suggested there is a disconnect between the survey results and the diversity statement goals of "attracting, developing, and retaining volunteers who reflect the diversity of its membership to play key roles in leading the Society".
  • Compared with the total survey sample, non-white respondents perceived ASPHO to be less representative of a diverse organization; less than one-half of the non-white respondents believed membership reflected the diversity of the profession.
  • About 29% of non-white respondents encouraged ASPHO to "greatly increase" the number of programs to address diversity development, including having more diverse educational speakers, providing additional career development resources, and creating a welcoming environment.
  • More than half of survey respondents "do not know" whether ASPHO is supportive of addressing covert or overt instances of discrimination or bias at events or in print or online resources.

In light of these responses, the Board approved recommendations to

  • collect and summarize demographic data on ASPHO's volunteer workforce to inform members and support Leadership Development Committee efforts
  • highlight current diversity efforts on a new diversity page on the ASPHO website and through other communication channels and program information. Examples include conveying to members how ASPHO's Points of Diversity resource is used in determining volunteer appointments; relaying how diversity is incorporated into programming; and continuing to collect and benchmark both workplace and personal demographics.
  • increase the number of diversity-related resources on the ASPHO website
  • review ASPHO's diversity statement, written in 2010, and update it, if necessary.

ASPHO aspires to provide an inclusive and representative experience for every member and to promote equity in the workplace and in patient care. We encourage you to engage with the Diversity Special Interest Group and to send your comments to This email address is being protected from spambots. You need JavaScript enabled to view it. to help us build a more welcoming and responsive Society.

Eleny Romanos-Sirakis, MD, chair, Membership Committee
Nidhi Shah, DO, chair, Diversity Advisory Group
Betty Pace, MD, Board liaison, Membership Committee, and former chair, Diversity Advisory Group

December 2020

A Lifeline for Linguistic Isolation
Arun Gurunathan, MD

The number of individuals with limited English proficiency (LEP) has substantially increased in the past few decades, and over 4 million households have been termed "linguistically isolated." Describing complex hematologic/oncologic diagnoses, trials, and treatments is difficult enough even before considering language barriers.

To better understand the issue and improve communication, it is important to note the following:

Language barriers are a significant issue, with pediatric hematology/oncology-specific implications.

Language barriers in health care are associated with misdiagnoses and inappropriate treatment, decreased satisfaction and treatment adherence, and increased risk for harm.1

Looking specifically at the pediatric hematology/oncology population, one study showed that about a third of caregivers with LEP reported feeling that their child would have received better care if English was their primary language. In addition, caregivers with LEP were more likely to incorrectly identify whether their child was on a clinical trial compared with English-fluent caregivers.2 Language also is an important aspect of inequalities in clinical trial participation, as one study showed significant underrepresentation in pediatric oncology protocol participation for children with Spanish-speaking parents.3

Interpreters are crucial, and the type of interpreter matters.

It is well established that families with LEP are less satisfied when family or ad hoc interpreters (eg, bilingual unit clerks, custodial staff, etc.) were used instead of professional interpreters4. One study showed that ad hoc interpreters made errors twice as often as professional interpreters, and 77% of their errors had potential clinical consequences.1

Not surprisingly, a study looking at patient, provider, and interpreter perspectives found that in-person professional interpretation is generally preferred.5 Maximizing in-person interpreter availability is important. However, given that in-person interpretation is not always feasible—especially in the setting of COVID-19—when practices are weighing other options, it is worth noting that families with LEP who received video interpretation were more likely to retain the information provided compared to families who received audio-only telephonic interpretation.1

Additional resources are helpful.

An important complement to using a professional interpreter is the use of materials/handouts in the patient's/family's primary language. Some centers have gone further, with one example being the development of LEP Patient Family Advocates who have 3 roles: specialized medical interpreter, cultural liaison, and healthcare systems advocate/adjunct case management.6

Tips when working with interpreters:

  • If possible, talk to the interpreter beforehand to briefly summarize what you will be discussing.
  • Speak directly to the patient/family, not to the interpreter.
  • Speak relatively slowly and in short sentences, with pauses for the interpreter to interpret.
  • Even with a professional interpreter, still strive (like with any patient/family) to speak as simply as possible and minimize medical jargon.
  • Encourage the interpreter to ask clarifying questions and alert you to potential cultural misunderstandings.
  • Be clear that everything you say and everything the patient/family says should get interpreted; address the issue if there is concern that not everything is being interpreted (eg, the patient gives a long response but the interpreter says only a few words).

While some of this information may not be new, it is important to continually be mindful of the difficulties faced by patients/families with LEP and the tools that can improve communication and patient care.

References

  1. Lion KC, Brown JC, Ebel BE, et al. Effect of telephone vs video interpretation on parent comprehension, communication, and utilization in the pediatric emergency department: a randomized clinical trial. JAMA Pediatr. 2015;169(12):1117-1125.
  2. Zamora ER, Kaul S, Kirchhoff AC, et al. The impact of language barriers and immigration status on the care experience for Spanish-speaking caregivers of patients with pediatric cancer. Pediatr Blood Cancer. 2016;63(12):2173-2180.
  3. Aristizabal P, Singer J, Cooper R, et al. Participation in pediatric oncology research protocols: racial/ethnic, language, and age-based disparities. Pediatr Blood Cancer. 2015;62(8):1337-1344.
  4. Lee LJ, Batal HA, Maselli JH, Kutner JS. Effect of Spanish interpretation method on patient satisfaction in an urban walk-in clinic. J Gen Intern Med. 2002;17(8):641-645.
  5. Locatis C, Williamson D, Gould-Kabler C, et al. Comparing in-person, video, and telephonic medical interpretation. J Gen Intern Med. 2010;25(4):345-350.
  6. Gil S, Hooke MC, Niess D. The Limited English Proficiency Patient Family Advocate Role: Fostering Respectful and Effective Care Across Language and Culture in a Pediatric Oncology Setting. J Pediatr Oncol Nurs. 2016;33(3):190-198.

By Arun Gurunathan, MD, Member, Diversity Advisory Group

Special Feature

April 2020

Interview with Dr. Bill Woods
Stella M. Davies, MBBS PhD

ASPHO is pleased to launch its eNews Special Feature Member Interview Series with a conversation with Dr. Bill Woods, MD, Past President and recipient of the 2011 Distinguished Career Award, about his many contributions to the field and to the Society. Dr. Woods recently announced his retirement from Children's Healthcare of Atlanta/Emory University. ASPHO member Stella M. Davies, MBBS PhD, recently interviewed Dr. Woods for eNews.

WoodsWilliam300Pediatric hematology/oncology (PHO) has come an enormous distance over the last 40 years. One person leading that charge from the outset was William (Bill) G. Woods, MD, the inaugural interviewee of this new ASPHO series of interviews with key figures in PHO. Bill was ASPHO’s president between 2006 and 2008 and received the ASPHO Distinguished Career Award in 2011. He has devoted his life to a combination of basic and clinical research and has seen childhood cancer change from a catastrophic diagnosis to a scary but largely treatable illness.

Bill is well known for his encyclopedic knowledge of the PHO literature and his ability to cut to the central core of any clinical problem. However, Bill is loved for his kindness, generosity of spirit, and the guidance and mentorship he has given to thousands—patients, families and practitioners—in the field of PHO.

This writer was lucky enough to talk about the past and future of PHO, and of ASPHO, with Bill on a bright, sunny day when COVID-19 concerns were pushed into the background for a brief time.

Stella M. Davies (SMD): Bill, why did you decide to go into pediatric oncology?

William G. Woods (WGW): In medical school, I heard that the intelligent folk all go into internal medicine, but I discovered during my training that I had a “pediatric personality”—it’s all about “how happy are you with the people around you?” I had never thought I would be an oncologist, but as a resident I noticed that the children who crawled under my skin—you know, the ones who stick with you—were all kids with cancer, and I suffered right alongside them. I also found intellectual fascination in the science—remember this was back before anybody knew what an oncogene was!

SMD: What are the most important changes you have seen in PHO during the last 40 years?

WGW: First, of course, chemotherapy development that worked in animal models appeared to work better in pediatric than adult cancer, giving us the tools to cure cancer. Second, the formation of the cooperative groups. Mortality in PHO fell briskly after the formation of the cooperative groups, and the group strategy spread later to Europe, where further advances were made. In more recent years, development of small molecule inhibitors and now immunotherapy are moving the field forward briskly.

SMD: Why were cooperative groups more successful in PHO than in any other field of medicine?

WGW: One important factor has been that children with cancer historically were generally all referred promptly to academic medical centers for care. Pediatric oncologists agreed as early as the 1950s that we needed to band together to ever make progress in what is, mercifully, a very rare disease. The other important factor has been the culture and characteristics of pediatric oncologists—we are natural “groupies” and love to share, collaborate, discuss, and work together. Also, our field has always focused on the children and not on finance, making cooperative care easier.

SMD: Bill, we have chosen a field in which sometimes, despite our best efforts, children are lost. Has that become easier to handle over the years?

WGW: This never gets easier, but it is a privilege to be with families, helping them on the most difficult days of their lives. This is where the art of medicine takes over from the science.

SMD: Would you recommend this career to someone just starting out today?

Read the rest of the interview.

August 2020

On the Importance of Mentorship: An ASPHO Mentee Shares Her Experience
Trisha Larkin, MD MBA

A career is a journey that you embark on with others. Mentors can help navigate all the twists and turns you are guaranteed to encounter. Good mentorship can be a tremendous asset along your path and should be sought. Mentors can teach through words, provide us with care and respect, and empower us to confidently approach the next steps in our careers. The ASPHO Mentoring Program was a unique opportunity that I am grateful to have seized. Through the program, every mentor-mentee relationship is different and may be tailored to your needs as a trainee or junior faculty.

I was fortunate to be paired with Dr. Tim Cripe from Nationwide Children's based on my interests in academic medicine and translational research. I was in a small fellowship program and wanted to learn more about how programs with multiple fellows per year approached their curriculum. Dr. Cripe was fantastic about sharing academic resources to complement what I received in my fellowship program and in providing an outside perspective about my research. Having an external mentor translated into benefitting from a wider spectrum of experience and wisdom and a chance to develop thought processes outside of my home institution's culture. He also provided invaluable insight about building my CV, career decisions such as considerations for choosing an additional subspecialty fellowship, factors to weigh in contract negotiation, and how metrics for production can be measured. I found that his objectiveness assisted me in making decisions and envisioning goals for transitioning into the next steps of my career as junior faculty.

Beyond providing advice specific to career development, a mentor-mentee relationship creates opportunities for the mentor to share a wide range of stories about their experiences that include both the successes as well as the pitfalls that the growth of any medical professional is bound to endure. Dr. Cripe shared personal stories with me that were encouraging and reaffirmed that everyone's path to success is different. In a rigorous career that can have emotional tolls, it was invaluable to hear his perspective on prioritizing a healthy work-life balance while still carving out an impactful career. I often found that our conversations were inspirational and reassuring at pivotal times during my fellowship. In a unique way, his mentorship afforded me the opportunity to reach beyond my own institutional circle to complement local mentors. We often think of mentoring in terms of the individuals in close proximity, but participating in this program granted me a remote mentor, which is extremely valuable during times when in-person meetings are prevented by extraneous events such as our current COVID-19 climate.

Fellowship can laden you with fears about the future as intense clinical and research demands mount pressure on young physicians. At times, there can be a worry that what you love about this career path has to be sacrificed to obtain the best faculty positions, secure grant funding, and attain opportunities. Considering the time and effort you have already invested in your career, guidance from someone who has already endured a similar journey can be vital in your growth and development. Active participation in the ASPHO mentorship program allows you to connect with professionals with a myriad of experiences and can be invaluable in helping you shape your ideal version of the specialty. I encourage early career professionals to seize the opportunity to participate.

Trisha Larkin, MD MBA
Clinical Fellow in Neuro-Oncology
St. Jude Children's Research Hospital

The Special Feature section of eNews highlights member-authored opinion pieces on broad issues in pediatric hematology/oncology that are of interest to ASPHO's diverse membership.

Copyright © 2020 by the American Society of Pediatric Hematology/Oncology. All rights reserved. The views and opinions expressed in the Feature Articles are those of the author alone and do not imply an opinion on the part of ASPHO, its Board of Trustees or staff. The information in this newsletter is intended to provide readers with resources and information that they may find useful and of interest and is only current as of the publication date. ASPHO is not liable to any party as a result of their reliance on the information, recommendations, services, or resources discussed or made available through this newsletter.

December 2020

An Interview with Dr. Susan Blaney
Shiley Aguilar, APRN NP-C

As part of the ASPHO eNews Special Feature Member Interview Series, we are pleased to present a conversation with Susan M. Blaney, MD, Director of Texas Children's Cancer and Hematology Centers. ASPHO Communications Committee member Shiley Aguilar, APRN NP-C, recently interviewed Dr. Blaney for eNews.

Dr. Susan BlaneySusan M. Blaney, MD, is vice chair of the Children's Oncology Group, Elise C. Young Chair of Pediatric Oncology and section chief of Hematology/Oncology at Baylor College of Medicine, and one of the founding members of the Pediatric Brain Tumor Consortium. She has served in numerous leadership roles and has been the recipient of many awards and honors, including the NCI Director's Service Award in 2017 and the Women of Excellence Award in 2019 at Baylor College of Medicine.

Dr. Blaney's career has been marked by her contribution to scientific advancements of PHO through research and the development of new agents and therapeutic strategies, as well as her influence through mentorship of practitioners and, of course, her impact on the innumerable children and families she has cared for throughout the years. Her contributions to PHO have undoubtedly left an indelible mark.

Shiley L. Aguilar (SLA): Can you tell us why you decided to go into pediatric hematology/oncology?

Susan M. Blaney (SMB): It is a privilege to take care of children and work with their families during what is one of the most difficult, if not the most difficult, time any child or family will face. The positive difference that the provider team can make in helping a family navigate through this journey is tremendous. In addition, pediatric hematology/oncology is a scientifically dynamic and rapidly changing field. The challenges of how to most effectively and efficiently incorporate new knowledge into the care of patients are both complex and rewarding.

SLA: What are the most important changes you have seen in PHO during your career?

SMB: The most important changes that I have seen in PHO during my career are related to our increased understanding of oncogenesis and associated refinements in risk stratification. The rapid advances in classification of each child's malignancy at the "omic" level, coupled with therapeutic advances in precision medicine through both "targeted" as well as immune-based treatment approaches, have led to new strategies for the treatment of childhood cancers. This new knowledge has also presented the field with significant new challenges in terms of when and how to best incorporate such treatments into cancer care. There is no doubt that our knowledge in this area will continue to advance and be associated with incremental increases in cure rates.

SLA: Can you share any particularly significant moments during your career, in terms of career opportunities, science, or patient care?

SMB: I have had tremendous opportunities that started early in my career. Highlights include the opportunity to train in clinical pharmacology research at the Pediatric Branch of the National Cancer Institute during my fellowship training at Walter Reed Army Medical Center. I was fortunate to have clinical mentorship from Dr. David Maybee and research mentorship from Drs. Frank Balis and David Poplack. This training provided a foundation that was critical to the rest of my career. Dr. Poplack subsequently provided my colleague, Dr. Stacey Berg, and me the opportunity to start a clinical pharmacology program at Texas Children's Cancer Center only several years out of fellowship training. Other highlights include serving as vice chair and then chair of COG's Phase 1 Consortium and then serving almost 10 years as vice chair of COG under the leadership of Dr. Peter Adamson.

Although leadership opportunities during my career have been a tremendous privilege, it has been a substantial honor and privilege to mentor many students, fellows, and faculty over the years. Celebrating their "firsts," such as manuscript publications, platform presentations, grant awards, and leadership positions, has created a series of incredible highlights.

The ultimate privilege that I have had during my career is caring for patients and their families. The trust that our patients and their families place in us as we make recommendations for their treatment and care is incredible. Their experiences put our lives into perspective in a way that is second to none.

SLA: You have had many outstanding leadership positions, including your current role as director of Texas Children's Cancer and Hematology Centers. What has your experience been as a woman in the field?

SMB: My experience as a woman in the field has been positive. There is no question that while raising a family you have to juggle many things, and there are days when you are exhausted. However, I was fortunate that my husband always pitched in and that I had good childcare. The latter investment was essential to providing me with the flexibility that I needed during the formative stages of my career.

SLA: What advice would you give to someone just starting a career in PHO?

SMB: Find an aspect of PHO about which you are passionate so that you can develop a niche that is yours at the local, national, or international level. Embrace opportunities as they arise, as you never know what doors they will open for you. Never stop asking questions. Have fun!

SLA: Once again, we want to thank you for taking the time to give us all insight into your experiences and for your many contributions to our field.

Copyright© 2020 by the American Society of Pediatric Hematology/Oncology. All rights reserved. The views and opinions expressed in the Feature Articles are those of the author alone and do not imply an opinion on the part of ASPHO, its Board of Trustees or staff. The information in this newsletter is intended to provide readers with resources and information that they may find useful and of interest and is only current as of the publication date. ASPHO is not liable to any party as a result of their reliance on the information, recommendations, services, or resources discussed or made available through this newsletter.

  • Products
    • KARE Toolkit: Knowledge and Assessment Resources
    • Webinars
    • ASPHOcast
    • Alexion Recording
    • 2024 Compensation Survey
    • Webinar Toolkit
    • Compensation and Benefits Report
    • View the Compensation and Benefits Survey Report
    • Compensation Tool
  • Online Review Course
  • Pediatric Blood & Cancer
    • Access Journal
    • Online Access Instructions
  • ASPHO eNews
    • August 2015 Enews
    • June 2015 Enews
    • April 2015 Enews
    • February 2015 Enews
    • December 2014 Enews
    • October 2014 Enews
    • August 2014 Enews
    • June 2014 Enews
    • April 2014 Enews
    • February 2014 Enews
    • December 2013 Enews
    • October 2013 Enews
    • August 2013 Enews
    • June 2013 Enews
    • April 2013 Enews
    • February 2013 Enews
    • October 2014 Enews
    • October 2015 Enews
    • December 2015 Enews
    • February 2016 Enews
    • April 2016 Enews
    • June 2016 Enews
    • August 2016 Enews
    • October 2016 Enews
    • December 2016 Enews
    • February 2017 Enews
    • April 2017 Enews
    • June 2017 Enews
    • August 2017 Enews
    • October 2017 Enews
    • December 2017 Enews
    • February 2018 Enews
    • April 2018 Enews
    • June 2018 Enews
    • August 2018 eNews
    • October 2018 eNews
    • February 2019 eNews
    • Member Insights: eNews 2018 Highlights
    • April 2019 eNews
    • June 2019 eNews
    • August 2019 eNews
    • October 2019 eNews
    • December 2019 eNews
    • February 2020 eNews
    • April 2020 eNews
    • June 2020 eNews
    • August 2020 eNews
    • October 2020 eNews
    • December 2020 eNews
    • April 2021 eNews
    • June 2021 eNews
    • August 2021 eNews
    • December 2021 eNews
    • February 2022 eNews
    • April 2022 eNews
    • June 2022 eNews
    • August 2022 eNews
    • October 2022 eNews
    • December 2022 eNews
    • February 2023 eNews
    • April 2023 eNews
    • June 2023 eNews
    • October 2023 eNews
    • December 2023 eNews
    • February 2024 eNews
    • March 2024 eNews
    • April 2024 eNews
    • June 2024 eNews
    • August 2024 eNews
    • October 2024 eNews
    • December 2024 eNews
    • February 2025 eNews
    • April 2025 eNews
    • June 2025 eNews
  • Pediatric Blood & Cancer - Call for Applications for Deputy Editor
  • October 2015 Enews
  • Advocacy Sample
  • News Briefs
  • Health Policy & Advocacy
    • 2016 August Advocacy Brief
    • 2016 December Advocacy Brief
    • 2017 February Advocacy Brief
    • 2017 May Advocacy Brief
    • 2017 September Advocacy Brief
    • 2017 November Advocacy Brief
    • 2018 Advocacy Brief - March
    • Contact Your Members of Congress
    • 2018-Advocacy-Brief-June
    • 2018-Advocacy-Brief-September
    • Advocacy Brief December 2018
    • 2019 Advocacy Brief - March
    • March 2019 Advocacy Brief
    • June 2019 Advocacy Brief
    • September 2019 Advocacy Brief
    • March 2020 Advocacy Brief
    • June 2020 Advocacy Brief
    • September 2020 Advocacy Brief
    • December 2020 Advocacy Brief
    • June 2021 Advocacy Brief
    • September 2021 Advocacy Brief
    • March 2022 Advocacy Brief
    • June 2022 Advocacy Brief
    • September 2022 Advocacy Brief
    • March 2024 Advocacy Brief
    • September 2024 Advocacy Brief
    • December 2024 Advocacy Brief
    • March 2025 Advocacy Brief
  • 2017 Workforce Survey Report
  • Help Fund the STAT Act
  • Practice and Quality
    • Choosing Wisely®
    • Position Paper
    • Endorsements
    • ASPHO Endorsements member only
Advertising, Exhibits, & Support | Career Center | Calendar | Contact Us
Terms of Use & Privacy Policy » © The American Society of Pediatric Hematology/Oncology®